NCT02012218已完成3 期
A Phase 3b, Multicenter, Open-label Exploratory Trial to Evaluate the Efficacy, Safety, and Subject Satisfaction With Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
Otsuka Pharmaceutical Development & Commercialization, Inc.23 个研究点 分布在 1 个国家目标入组 61 人开始时间: 2013年11月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 61
- 试验地点
- 23
- 主要终点
- Mean Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
研究概览
简要总结
The objectives of this exploratory trial are to evaluate the efficacy, safety, and subjects' subjective satisfaction when switching to adjunctive brexpiprazole in subjects with MDD who have responded inadequately to preceding adjunctive drug therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of MDD
- •In current major depressive episode of ≥ 8 weeks in duration and includes an inadequate response to at least 1 adjunctive treatment.
- •Positive history of at least 1 additional failure to an adequate monotherapy antidepressant treatment.
- •HAM-D17 total score≥ 18
- •Currently receiving SSRI of SNRI with adjunctive treatment for at least 6 weeks before screening.
- •Willing to discontinue use of all prohibited psychotropic medications
- •Historical positive serological results for HIV, hepatitis B/C
- •Able to provide written informed consent prior to the initiation of any protocol-required procedures
- •Subjects who could potentially benefit from adjunctive treatment with Brexpiprazole
排除标准
- •Sexually active women of childbearing potential
- •Male subjects not practicing 2 different methods of birth control
- •Females who are breastfeeding and/or who have a positive pregnancy test result
- •Subjects who have received ECT for the current major depressive episode.
- •Subjects who have had an inadequate response to ECT
- •Current need for involuntary commitment or who have been hospitalized within 4 weeks of screening
- •Current Axis I (DSM-IV-TR)
- •Current Axis II (DSM-IV-TR)
- •Subjects experiencing hallucinations, delusions, or any psychotic symptomatology in the current major depressive episode.
- •Subjects receiving new onset psychotherapy.
- •Subjects who answer "Yes" on the C-SSRS Suicidal Ideation Item 4, Item 5, or on any of the 5 C-SSRS Suicidal Behavior Items
- •Subjects who have met DSM-IV-TR criteria for substance abuse or dependence within the past 180 days
- •Hypothyroidism or hyperthyroidism
- •Clinically significant neurological, hepatic, renal, metabolic, haematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorders
- •Currently treated with insulin for diabetes
- •Uncontrolled hypertension or symptomatic hypotension, or orthostatic hypotension
- •Known ischemic heart disease or history of myocardial infarction, congestive heart failure, angioplasty, stenting, or coronary artery bypass surgery
- •Epilepsy or history of seizures
- •Positive drug screen
- •The following laboratory test and ECG results are exclusionary:
- •Platelets ≤ 75,000/mm3
- •Hemoglobin ≤ 9 g/dL
- •Neutrophils, absolute ≤ 1000/mm3
- •AST > 2 × ULN
- •ALT > 2 × ULN
- •CPK > 3 × ULN, unless discussed with and approved by the medical monitor
- •Creatinine ≥ 2 mg/dL
- •HbA1c ≥ 7.0%
- •Abnormal free T4 (Note: Free T4 is measured only if result for TSH is abnormal.)
- •QTcF ≥ 470 msec for females and ≥ 450 msec for males
- •Treatment with an MAOI or EMSAM within 14 days of the Baseline visit.
- •Use of benzodiazepines and/or hypnotics within 7 days prior to the first dose of IMP
- •Use of oral neuroleptics within 7 days prior or long-acting approved atypical antipsychotics ≤ 1 full cycle plus ½ cycle prior to the first dose of IMP
- •Subjects who would be likely to require prohibited concomitant therapy during the trial.
- •Subjects who previously participated in any prior brexpiprazole trial
- •History of neuroleptic malignant syndrome or serotonin syndrome
- •History of true allergic response to more than one class of medications
- •Prisoners or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.
- •Subjects who participated in a clinical trial within the last 180 days or who participated in more than 2 clinical trials within the past year.
- •Any subject who, in the opinion of the investigator or medical monitor, should not participate.
研究组 & 干预措施
ADT and Brexpiprazole
Experimental
ADT and Brexpiprazole
干预措施: ADT (Drug)
ADT and Brexpiprazole
Experimental
ADT and Brexpiprazole
干预措施: Brexpiprazole (Drug)
结局指标
主要结局
Mean Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
时间窗: Baseline and Week 6
The MADRS was used as the primary efficacy assessment of level of depression. The MADRS was administered using the Structured Interview Guide for the MADRS. Detailed instructions were provided.The MADRS consists of 10 items each, with 7 defined grades of severity (ie, 0 to 6, with 0 being the "best" rating and 6 being the "worst" rating). The MADRS total score is the sum of ratings for all 10 items; therefore, possible total scores range from 0 to 60. The MADRS total score least squares (LS) mean changes from baseline to Week 6 is mentioned below.
次要结局
未报告次要终点
研究者
研究点 (23)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV InfectionChronic HCV InfectionNCT02021656Gilead Sciences384
已完成
3 期
Efficacy and Safety of Lanadelumab (SHP643) in Japanese Participants With Hereditary Angioedema (HAE)Hereditary Angioedema (HAE)NCT04180163Shire12
已完成
3 期
Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)Small Cell Lung CancerNCT03061812AbbVie444
Unknown
3 期
PANVAC™-VF Vaccine for the Treatment of Metastatic Pancreatic Cancer After Failing a Gemcitabine-Containing RegimenPancreatic CancerNCT00088660Therion Biologics Corporation250
已完成
3 期
Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS ImagingMagnetic Resonance ImagingNCT01660841Bayer223